Cefozopran

Drug Profile

Cefozopran

Alternative Names: Firstcin; SCE 2787

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Takeda
  • Developer Takeda; Wyeth K.K.
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Bacterial infections; Bacterial meningitis; Paediatric infections; Pneumonia

Most Recent Events

  • 31 Dec 2003 Wyeth-Lederle Japan is now called Wyeth K.K.
  • 13 Oct 2000 Discontinued-II for Bacterial infections in Germany (IV-injection)
  • 13 Oct 2000 Launched for Bacterial meningitis in Japan (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top